adMare Bio Innovations

KisoJi Biotechnology is an early-stage biotech company specializing in antibody development for cancer treatment. Its innovative platform combines multi-species transgenic mice with AI-driven antibody fingerprinting, enabling the identification of optimal lead candidates and the creation of robust, manufacturable multi-specific antibodies.

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

Find Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare inflammatory and fibrotic diseases affecting the airways, liver, and gastrointestinal systems. Founded in 2020 and headquartered in Saint-Laurent, Canada, the company specializes in creating G protein-coupled receptor (GPCR) allosteric modulators and employs a peptide discovery engine to design peptide-based therapies. These therapies target transmembrane domains of receptors that play crucial roles in various biological processes, facilitating the development of next-generation treatments for autoimmune conditions. By leveraging advanced technology and research capabilities, Find Therapeutics aims to address unmet medical needs in the field of inflammatory diseases.

Specific Biologics is a biotechnology company focused on developing innovative gene-editing technologies for treating genetic diseases at their source within the body. The company's core technology involves a dual-cleaving nuclease that can be safely delivered to cells, leveraging the cell's natural DNA repair mechanisms to either enhance repair or create predictable deletions. This approach aims to address various genetic conditions by precisely editing the genome.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

Immugenia is an early-stage immuno-oncology company developing a novel CAR therapy approach by engineering hematopoietic stem cells to treat cancer and prevent relapses.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Specific Biologics is a biotechnology company focused on developing innovative gene-editing technologies for treating genetic diseases at their source within the body. The company's core technology involves a dual-cleaving nuclease that can be safely delivered to cells, leveraging the cell's natural DNA repair mechanisms to either enhance repair or create predictable deletions. This approach aims to address various genetic conditions by precisely editing the genome.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

Accel-Rx is a business accelerator focused on companies based in the health sciences sector.

Bright Angel Therapeutics develops novel therapeutics targeting stress responses crucial for fungi's survival, virulence, and drug resistance. Its platform aims to enhance current treatment efficacy and eliminate drug resistance, combating life-threatening fungal infections.

NEOMED Institute is a not-for-profit organization focused on transforming the drug development landscape through a public-private partnership model. By addressing the gap between basic research and advanced drug development, NEOMED offers expertise and funding to academic laboratories and early-stage biotechnology companies. Its mission is to facilitate the transition of innovative therapeutic approaches to the proof-of-concept stage in humans, thereby enhancing their value for pharmaceutical partners. NEOMED aims to empower small and medium enterprises, enabling them to navigate the complexities of drug discovery and development, and align academic innovations with industry requirements.